DAK-Gesundheit is procuring pharmaceutical products, specifically a non-exclusive discount agreement for Natalizumab (ILO dosage form only), ATC L04AA23, for the period 1 September 2026 to 31 August 2028. The estimated value is 1 EUR. This procurement is located in Hamburg, Germany. The submission deadline is 5 July 2028. Notice, tender documents and submission instructions are available on the oeffentlichevergabe.de portal.
Risk analysis is not yet available for this country's tenders. Currently supported: Estonia, Latvia, Lithuania, Poland, France, UK, Denmark, Netherlands, Norway, and Finland.
Get an AI-powered winning strategy tailored to this tender. Includes win probability score, key opportunities and challenges, recommended bid focus areas, competitive positioning insights, and actionable recommendations to maximize your chances.
LoginUpgrade to see which companies are likely to bid on this tender, based on historical procurement data.
LoginAI extracts and organizes all requirements from tender documents — mandatory qualifications, technical specifications, financial conditions, and submission rules — clearly categorized so you know exactly what's needed to bid.
Login1 documents available with AI summaries
Sign up to view document summaries and analysis
Comprehensive quality analysis of this tender scoring legal compliance, clarity, completeness, fairness, practicality, data consistency, and sustainability on a 0-100 scale with detailed breakdown and recommendations.
LoginHello! I'm your AI assistant for this tender. I can help you understand requirements, deadlines, eligibility criteria, and provide strategic insights.
No credit card required